Investors become accustomed to inertia whereas when the share price is rising every potentiality appears possible, even likely.
Confirmation will be provided by clinical proof of concept but in the case of an efficient and safe delivery vehicle for RNA therapeutics the stakes are so high. Potential partners can wait but will they miss out in favour of a speculative investment in the technology on the basis of risk versus reward. What is the reward profile for a transformative safe and efficient delivery platform?
Pharma are accustomed to running clinical trials costing hundreds of millions with no guarantee of success. The decision to partner in a transformative clinical trial that has taken decades to crystallise until at this point in time it has a laser focus, may not be as difficult as it appears with a falling share price.
PYC Price at posting:
6.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)